Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Benzoyl peroxide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
e Acnecide 10% gel Do not use Acnecide 10% gel if you are:
Acnecide 10% gel Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Product code: P202640-0 Product description: ACNECIDE 10 GEL 30 Market: GB Article: Leaflet Flat size: 180×315 Font size: 9 pt Fold size: 180×26,25 Pharmacode: 2675
PMS 432U
GRAPHIC DESIGNER: Guillaume ANDRÉ INDUSTRIALIZATION DEPARTMENT
LABORATOIRES GALDERMA – Z.I. Galderma – 74540 ALBY-SUR-CHÉRAN – FRANCE
DIELINES
NOTICE VERSO 180×315 PLAN n° MT.09.DRA.0352.R02.2 If you use more Acnecide 10% gel than you should or accidentally swallow the gel
Like all medicines, this medicine can cause side effects, although not everybody gets them. Severe allergic reactions have occurred in a small number of people but their frequency is not known. STOP using Acnecide 10% gel and tell your doctor immediately if you develop a severe allergic reaction. Signs of severe allergic reactions may include:
Acnecide 10% gel
What Acnecide 10% gel contains The active substance is benzoyl peroxide. Every gram of Acnecide 10% gel contains 100 mg (10%) benzoyl peroxide (as hydrous benzoyl peroxide). The other ingredients are docusate sodium, disodium edetate, poloxamer, carbomer, propylene glycol (E1520), acrylates copolymer, glycerol, colloidal anhydrous silica, purified water and sodium hydroxide to adjust the pH. What Acnecide 10% gel looks like and contents of the pack Acnecide 10% gel is a white to off-white gel. It is available in tubes of 30g and 40g from your pharmacist. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Galderma (UK) Limited, Evergreen House North, Grafton Place, London, NW1 2DX, UK Tel: 0300 3035674 E-mail: [email protected] PL 10590/0074 Manufacturer: Laboratoires Galderma, ZI- Montdésir, 74540 Alby-sur-Chéran, France. This leaflet was last revised in May 2025.
P202640-0
7. General advice for people with acne
Product code: P202640-0 Product description: ACNECIDE 10 GEL 30 Market: GB Article: Leaflet Flat size: 180×315 Font size: 9 pt Fold size: 180×26,25 Pharmacode: 2675
PMS 432U
GRAPHIC DESIGNER: Guillaume ANDRÉ INDUSTRIALIZATION DEPARTMENT
LABORATOIRES GALDERMA – Z.I. Galderma – 74540 ALBY-SUR-CHÉRAN – FRANCE
DIELINES
Acnecide 10% w/w Gel comes as gel. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Acnecide 10% w/w Gel is benzoyl peroxide.
Medicines with the same active substance, strength and form include: Acnecide 5% w/w Gel, Acnecide Face 2.5% w/w Gel, Acnecide Face 5% w/w Gel. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Acnecide 10% w/w Gel, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Topical therapy for the treatment of acne vulgaris.
Acnecide 10% w/w Gel is indicated in adults and adolescents aged 12 years and over.
For external use only.
Adults and adolescents aged 12 years and over:
Before each application, the skin should be cleaned and dried. The gel should be applied in a thin layer once daily or as directed to the affected areas. The extent of any drying or peeling may be adjusted by modifying the dosage schedule.
It is recommended to initiate the treatment with benzoyl peroxide 2.5 or 5% gel. In case adequate results are not achieved with the 5% gel and the 5% gel is well tolerated, the treatment with benzoyl peroxide 10% gel may be started.
Paediatric population:
The safety and efficacy of Acnecide 10% w/w Gel in children aged less than 12 years have not been established.
Method of administration:
Acnecide is indicated for external (dermatological) use only.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
For external use only.
Acnecide may cause swelling and blistering of the skin, if any of these symptoms occur, this medication has to be discontinued.
A mild burning sensation will probably be felt on first application and some reddening and peeling of the skin will occur within a few days. During the first weeks of treatment a sudden increase in peeling will occur in most patients. This is not harmful and will normally subside within a day or two if treatment is temporarily discontinued. If severe irritation occurs, patients should be directed to use the medication less frequently, to temporarily discontinue use or to discontinue use altogether.
Patients should be advised that excessive application will not improve efficacy, but may increase the risk of skin irritation.
Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy may occur, which sometimes may be severe, especially with the use of peeling, desquamating, or abrasive agents.
Benzoyl peroxide gel should not come into contact with the eyes, mouth, angles of the nose or mucous membranes. If the preparation enters the eye, wash thoroughly with water. Caution should be exercised when applying the drug to the neck and other sensitive areas.
As Acnecide may cause increased sensitivity to sunlight, sunlamps should not be used and deliberate or prolonged exposure to sunlight or UV radiation should be avoided or minimised. When strong sunlight cannot be avoided, patients should be advised to use a sun-protection product with a protection factor of at least SPF 30 and UVA protection and wear protective clothing.
Contact with any coloured material including hair and dyed fabrics may result in bleaching or discoloration.
Due to the risk of sensitisation, benzoyl peroxide gel should not be applied on damaged skin.
This medicinal product contains 40 mg of propylene glycol (E1520) in each gram, which is equivalent to 4.0% w/w. It may cause skin irritation.
No interaction studies have been performed; however, drugs with desquamative, irritant and drying effects should not be used concurrently with benzoyl peroxide gel.
Pregnancy
There is no safety concern relating to the effects of cutaneously applied benzoyl peroxide on teratogenicity, embryotoxicity, or peri- and post- natal development from animal data. In widespread clinical use for the cutaneous treatment of acne vulgaris, at concentrations up to 10% w/w for several decades, benzoyl peroxide has never been associated with such effects. Acnecide should only be used by a pregnant woman if clearly needed.
Breast-feeding
It is unknown whether benzoyl peroxide/metabolites are excreted in human milk. A risk to the new-borns/infants cannot be excluded. Caution should be exercised when benzoyl peroxide is administered to a nursing woman and the preparation should not be applied on the chest to avoid accidental transfer to the infant.
Fertility
There is no safety concern relating to the effects of cutaneously applied benzoyl peroxide on reproductive function or fertility from animal data. In widespread clinical use for the cutaneous treatment of acne vulgaris, at concentrations up to 10% w/w for several decades, benzoyl peroxide has never been associated with such effects.
Acnecide Gel has no or negligible influence on the ability to drive and use machines.
The adverse reactions resulting from clinical trials are all skin disorders. They are reversible when treatment is reduced in frequency or discontinued.
The following categories are used to indicate the frequency of occurrence of adverse effects:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥ 1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (frequency cannot be estimated from the available data).
They are presented in the table below:
Skin and subcutaneous tissue disorders
Very common (≥1/10)
Dry skin
Erythema
Skin exfoliation (peeling)
Skin burning sensation
Common (≥1/100 to <1/10)
Pruritus
Pain of skin (pain, stinging),
Skin irritation (irritant contact dermatitis)
Uncommon (≥1/1,000 to <1/100)
Allergic contact dermatitis
Swelling of the face and allergic reactions, including application site hypersensitivity and anaphylaxis (frequency not known) have been reported during post-marketing surveillance.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website at: https://yellowcard.mhra.gov.uk - or search for MHRA Yellow Card in the Google Play or Apple App Store.
Benzoyl peroxide gel is a preparation indicated for topical treatment only. If the medication is applied excessively, no more rapid or better results will be obtained and severe irritation might develop. In this event, treatment must be discontinued and appropriate symptomatic therapy should be instituted.
Ask anything about Acnecide 10% w/w Gel. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.